AUTL — Autolus Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $431.15m
- $221.50m
- $10.12m
- 16
- 24
- 59
- 23
Annual cashflow statement for Autolus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -142 | -142 | -149 | -208 | -221 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 18.6 | 11.7 | 25.4 | 56.9 | 30.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.41 | 4.14 | 3.97 | 0.292 | -23.7 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -118 | -118 | -112 | -146 | -206 |
| Capital Expenditures | -14.7 | -8.86 | -10.8 | -11 | -34.8 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | — | -360 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -14.7 | -8.86 | -10.8 | -11 | -395 |
| Financing Cash Flow Items | — | -12 | -10.4 | -0.91 | -31 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 74.4 | 284 | 224 | -0.883 | 590 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -57.3 | 157 | 72.1 | -142 | -11.5 |